Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein-Reference-Cited by-同舟云学术

Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein

Published:2014-04 Issue: Volume:454-455 Page:139-144
ISSN:0042-6822
Container-title:Virology
language:en
Short-container-title:Virology

Author:

Bates John T.,Keefer Christopher J.,Slaughter James C.,Kulp Daniel W.,Schief William R.,Crowe James E.

Funder

Clinical Scientist Award in Translational Research

the Pediatric Scientist Development Program

the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Publisher

Elsevier BV

Subject

Virology

Reference28 articles.

1. Palivizumab-resistant human respiratory syncytial virus infection in infancy;Adams;Clin Infect Dis,2010

2. Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore;Aiyegbo;PLoS One,2013

3. Anon, 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531–537.

4. Reversion of Somatic Mutations of the Respiratory Syncytial Virus-Specific Human Monoclonal Antibody Fab19 Reveal a Direct Relationship between Association Rate and Neutralizing Potency;Bates;J Immunol,2013

5. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function;Beeler;J Virol,1989

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complete combinatorial mutational enumeration of a protein functional site enables sequence‐landscape mapping and identifies highly‐mutated variants that retain activity;Protein Science;2024-07-11

2. Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65;Infectious Diseases and Therapy;2024-06-26

3. Broadening a SARS-CoV-1–neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution;Science Signaling;2023-08-15

4. New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus;Infection and Drug Resistance;2023-04

5. Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring;Microbiology Spectrum;2022-10-26